文献速递甲状腺疾病

抑制ALK信号可逆转STRN-ALK诱导的钠碘同向转运体下调并恢复甲状腺细胞摄碘

Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
PubMed 文献 · Thyroid · 2023-02-27

该临床前研究利用STRN-ALK驱动的甲状腺癌小鼠模型及多西环素诱导STRN-ALK表达的PCCL3正常甲状腺细胞,发现Nis下调在ALK驱动癌变早期即出现,STRN-ALK表达使NIS介导的摄碘下降四倍,ALK抑制剂克唑替尼和色瑞替尼可逆转该效应,selumetinib与ruxolitinib联用有累积效应。

要点

  • Nis下调在ALK驱动甲状腺癌变早期即出现,低分化癌中完全缺失。
  • STRN-ALK表达使NIS介导的摄碘下降四倍,克唑替尼和色瑞替尼可逆转。
  • selumetinib抑制MAPK信号可剂量依赖性恢复NIS并使其重新分布至细胞膜。

核心结论

  • 这项临床前研究显示,ALK融合诱导的NIS下调是RAI难治的前提,可通过直接抑制ALK或其下游信号通路在甲状腺细胞中被逆转。

研究设计与样本

  • 临床前研究,使用STRN-ALK驱动甲状腺癌小鼠模型分析NIS在不同癌变阶段的表达,并用多西环素诱导STRN-ALK表达的PCCL3正常甲状腺细胞进行体外实验。

主要发现

  • Nis下调在ALK驱动甲状腺癌变早期即出现,甚至在高分化癌阶段即存在,在低分化甲状腺癌中完全缺失。
  • 甲状腺细胞急性表达STRN-ALK导致MAPK、JAK/STAT3和PI3K/AKT/mTOR信号输出增加,并伴有多数甲状腺分化及碘代谢/转运基因的显著ALK依赖性下调。
  • STRN-ALK表达诱导膜性NIS显著丢失及NIS介导的RAI摄取下降四倍,克唑替尼和色瑞替尼可逆转上述改变。
  • selumetinib抑制MAPK信号后,STRN-ALK表达甲状腺细胞中NIS呈强剂量依赖性恢复并重新分布至细胞膜,与JAK1/2抑制剂ruxolitinib联用表现出累积效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Radioiodine (RAI) is commonly used for thyroid cancer treatment, although its therapeutic benefits are restricted to iodine-avid tumors. The RAI-refractory disease develops with tumor dedifferentiation involving loss of sodium-iodine symporter (NIS). Thyroid cancers driven by ALK fusions are prone to dedifferentiation, and whether targeted ALK inhibition may enhance RAI uptake in these tumors remains unknown. The aim of this study was to determine the levels of NIS expression during the progression of ALK fusion-driven thyroid cancer, assess the effects of ALK activation on NIS-mediated RAI uptake, and test pharmacological options for its modulation. Methods: The expression of NIS at different stages of ALK-driven carcinogenesis was analyzed using a mouse model of STRN-ALK-driven thyroid cancer. For in vitro experiments, a system of doxycycline-inducible expression of STRN-ALK was generated using PCCL3 normal thyroid cells. The STRN-ALK-induced effects were evaluated with quantitative reverse transcription polymerase chain reaction, Western blot, immunofluorescence, RNA sequencing, and gene sets pathways analyses. RAI uptake was measured using 131I. Treatment experiments were done with FDA-approved ALK inhibitors (crizotinib and ceritinib), MEK inhibitor selumetinib, and JAK1/2 inhibitor ruxolitinib. Results: We found that Nis downregulation occurred early in ALK-driven thyroid carcinogenesis, even at the stage of well-differentiated cancer, with a complete loss in poorly differentiated thyroid carcinomas. Acute STRN-ALK expression in thyroid cells resulted in increased MAPK, JAK/STAT3, and PI3K/AKT/mTOR signaling outputs associated with significant ALK-dependent downregulation of the majority of thyroid differentiation and iodine metabolism/transport genes, including Slc5a5 (Nis), Foxe1, Dio1, Duox1/2, Duoxa2, Glis3, Slc5a8, and Tg. Moreover, STRN-ALK expression in thyroid cells induced a significant loss of membranous NIS and a fourfold decrease of the NIS-mediated RAI uptake, which were reversed by ALK inhibitors crizotinib and ceritinib. In addition, a strong dose-dependent restoration of NIS with its membranous redistribution in STRN-ALK-expressing thyroid cells was observed after inhibition of MAPK signaling with selumetinib, which exhibited a cumulative effect with JAK1/2 inhibitor ruxolitinib. Conclusions: The findings of this preclinical study showed that ALK fusion-induced downregulation of NIS, the prerequisite of RAI refractoriness, could be reversed in thyroid cells by either direct inhibition of ALK or its downstream signaling pathways.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nikitski AV, Condello V, Divakaran SS, et al. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells. Thyroid. 2023. PMID: 36585857. doi:10.1089/thy.2022.0533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。